 | • レポートコード：MRC2-11QY03285 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はバイオシミラーインスリンのグローバル市場について調査・分析したレポートです。種類別（インスリングラルギンバサグラル、インスリンランタス）市場規模、用途別（I型糖尿病、II型糖尿病）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別バイオシミラーインスリンの競争状況、市場シェア ・世界のバイオシミラーインスリン市場：種類別市場規模 2015年-2020年（インスリングラルギンバサグラル、インスリンランタス） ・世界のバイオシミラーインスリン市場：種類別市場規模予測 2021年-2026年（インスリングラルギンバサグラル、インスリンランタス） ・世界のバイオシミラーインスリン市場：用途別市場規模 2015年-2020年（I型糖尿病、II型糖尿病） ・世界のバイオシミラーインスリン市場：用途別市場規模予測 2021年-2026年（I型糖尿病、II型糖尿病） ・北米のバイオシミラーインスリン市場分析：米国、カナダ ・ヨーロッパのバイオシミラーインスリン市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのバイオシミラーインスリン市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のバイオシミラーインスリン市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのバイオシミラーインスリン市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Eli Lilly、Boehringer Ingelheim、Merck、Pfizer、Biocon、Mylan ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim’s biosimilar insulin glargine has got approval through European Medicines Agency’s (EMA’s) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
Market Analysis and Insights: Global Biosimilars Insulin Market
The global Biosimilars Insulin market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Biosimilars Insulin Scope and Market Size
Biosimilars Insulin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilars Insulin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Biosimilars Insulin market is segmented into
Insulin Glargine Basaglar
Insulin Lantus
Segment by Application, the Biosimilars Insulin market is segmented into
Type I Diabetes
Type II Diabetes
Regional and Country-level Analysis
The Biosimilars Insulin market is analysed and market size information is provided by regions (countries).
The key regions covered in the Biosimilars Insulin market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Biosimilars Insulin Market Share Analysis
Biosimilars Insulin market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Biosimilars Insulin business, the date to enter into the Biosimilars Insulin market, Biosimilars Insulin product introduction, recent developments, etc.
The major vendors covered:
Eli Lilly
Boehringer Ingelheim
Merck
Pfizer
Biocon
Mylan
…
1 Study Coverage
1.1 Biosimilars Insulin Product Introduction
1.2 Market Segments
1.3 Key Biosimilars Insulin Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Biosimilars Insulin Market Size Growth Rate by Type
1.4.2 Insulin Glargine Basaglar
1.4.3 Insulin Lantus
1.5 Market by Application
1.5.1 Global Biosimilars Insulin Market Size Growth Rate by Application
1.5.2 Type I Diabetes
1.5.3 Type II Diabetes
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Biosimilars Insulin Market Size, Estimates and Forecasts
2.1.1 Global Biosimilars Insulin Revenue 2015-2026
2.1.2 Global Biosimilars Insulin Sales 2015-2026
2.2 Global Biosimilars Insulin, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Biosimilars Insulin Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Biosimilars Insulin Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Biosimilars Insulin Competitor Landscape by Players
3.1 Biosimilars Insulin Sales by Manufacturers
3.1.1 Biosimilars Insulin Sales by Manufacturers (2015-2020)
3.1.2 Biosimilars Insulin Sales Market Share by Manufacturers (2015-2020)
3.2 Biosimilars Insulin Revenue by Manufacturers
3.2.1 Biosimilars Insulin Revenue by Manufacturers (2015-2020)
3.2.2 Biosimilars Insulin Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Biosimilars Insulin Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Biosimilars Insulin Revenue in 2019
3.2.5 Global Biosimilars Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Biosimilars Insulin Price by Manufacturers
3.4 Biosimilars Insulin Manufacturing Base Distribution, Product Types
3.4.1 Biosimilars Insulin Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Biosimilars Insulin Product Type
3.4.3 Date of International Manufacturers Enter into Biosimilars Insulin Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Biosimilars Insulin Market Size by Type (2015-2020)
4.1.1 Global Biosimilars Insulin Sales by Type (2015-2020)
4.1.2 Global Biosimilars Insulin Revenue by Type (2015-2020)
4.1.3 Biosimilars Insulin Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Biosimilars Insulin Market Size Forecast by Type (2021-2026)
4.2.1 Global Biosimilars Insulin Sales Forecast by Type (2021-2026)
4.2.2 Global Biosimilars Insulin Revenue Forecast by Type (2021-2026)
4.2.3 Biosimilars Insulin Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Biosimilars Insulin Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Biosimilars Insulin Market Size by Application (2015-2020)
5.1.1 Global Biosimilars Insulin Sales by Application (2015-2020)
5.1.2 Global Biosimilars Insulin Revenue by Application (2015-2020)
5.1.3 Biosimilars Insulin Price by Application (2015-2020)
5.2 Biosimilars Insulin Market Size Forecast by Application (2021-2026)
5.2.1 Global Biosimilars Insulin Sales Forecast by Application (2021-2026)
5.2.2 Global Biosimilars Insulin Revenue Forecast by Application (2021-2026)
5.2.3 Global Biosimilars Insulin Price Forecast by Application (2021-2026)
6 North America
6.1 North America Biosimilars Insulin by Country
6.1.1 North America Biosimilars Insulin Sales by Country
6.1.2 North America Biosimilars Insulin Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Biosimilars Insulin Market Facts & Figures by Type
6.3 North America Biosimilars Insulin Market Facts & Figures by Application
7 Europe
7.1 Europe Biosimilars Insulin by Country
7.1.1 Europe Biosimilars Insulin Sales by Country
7.1.2 Europe Biosimilars Insulin Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Biosimilars Insulin Market Facts & Figures by Type
7.3 Europe Biosimilars Insulin Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Biosimilars Insulin by Region
8.1.1 Asia Pacific Biosimilars Insulin Sales by Region
8.1.2 Asia Pacific Biosimilars Insulin Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Biosimilars Insulin Market Facts & Figures by Type
8.3 Asia Pacific Biosimilars Insulin Market Facts & Figures by Application
9 Latin America
9.1 Latin America Biosimilars Insulin by Country
9.1.1 Latin America Biosimilars Insulin Sales by Country
9.1.2 Latin America Biosimilars Insulin Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Biosimilars Insulin Market Facts & Figures by Type
9.3 Central & South America Biosimilars Insulin Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Biosimilars Insulin by Country
10.1.1 Middle East and Africa Biosimilars Insulin Sales by Country
10.1.2 Middle East and Africa Biosimilars Insulin Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Biosimilars Insulin Market Facts & Figures by Type
10.3 Middle East and Africa Biosimilars Insulin Market Facts & Figures by Application
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Description and Business Overview
11.1.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Eli Lilly Biosimilars Insulin Products Offered
11.1.5 Eli Lilly Related Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Corporation Information
11.2.2 Boehringer Ingelheim Description and Business Overview
11.2.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Boehringer Ingelheim Biosimilars Insulin Products Offered
11.2.5 Boehringer Ingelheim Related Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Description and Business Overview
11.3.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck Biosimilars Insulin Products Offered
11.3.5 Merck Related Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Description and Business Overview
11.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Pfizer Biosimilars Insulin Products Offered
11.4.5 Pfizer Related Developments
11.5 Biocon
11.5.1 Biocon Corporation Information
11.5.2 Biocon Description and Business Overview
11.5.3 Biocon Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Biocon Biosimilars Insulin Products Offered
11.5.5 Biocon Related Developments
11.6 Mylan
11.6.1 Mylan Corporation Information
11.6.2 Mylan Description and Business Overview
11.6.3 Mylan Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Mylan Biosimilars Insulin Products Offered
11.6.5 Mylan Related Developments
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Description and Business Overview
11.1.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Eli Lilly Biosimilars Insulin Products Offered
11.1.5 Eli Lilly Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Biosimilars Insulin Market Estimates and Projections by Region
12.1.1 Global Biosimilars Insulin Sales Forecast by Regions 2021-2026
12.1.2 Global Biosimilars Insulin Revenue Forecast by Regions 2021-2026
12.2 North America Biosimilars Insulin Market Size Forecast (2021-2026)
12.2.1 North America: Biosimilars Insulin Sales Forecast (2021-2026)
12.2.2 North America: Biosimilars Insulin Revenue Forecast (2021-2026)
12.2.3 North America: Biosimilars Insulin Market Size Forecast by Country (2021-2026)
12.3 Europe Biosimilars Insulin Market Size Forecast (2021-2026)
12.3.1 Europe: Biosimilars Insulin Sales Forecast (2021-2026)
12.3.2 Europe: Biosimilars Insulin Revenue Forecast (2021-2026)
12.3.3 Europe: Biosimilars Insulin Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Biosimilars Insulin Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Biosimilars Insulin Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Biosimilars Insulin Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Biosimilars Insulin Market Size Forecast by Region (2021-2026)
12.5 Latin America Biosimilars Insulin Market Size Forecast (2021-2026)
12.5.1 Latin America: Biosimilars Insulin Sales Forecast (2021-2026)
12.5.2 Latin America: Biosimilars Insulin Revenue Forecast (2021-2026)
12.5.3 Latin America: Biosimilars Insulin Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Biosimilars Insulin Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Biosimilars Insulin Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Biosimilars Insulin Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Biosimilars Insulin Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Biosimilars Insulin Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Biosimilars Insulin Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Biosimilars Insulin Market Segments
Table 2. Ranking of Global Top Biosimilars Insulin Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Biosimilars Insulin Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Insulin Glargine Basaglar
Table 5. Major Manufacturers of Insulin Lantus
Table 6. Global Biosimilars Insulin Market Size Growth Rate by Application 2020-2026 (K MT)
Table 7. Global Biosimilars Insulin Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 8. Global Biosimilars Insulin Sales by Regions 2015-2020 (K MT)
Table 9. Global Biosimilars Insulin Sales Market Share by Regions (2015-2020)
Table 10. Global Biosimilars Insulin Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Biosimilars Insulin Sales by Manufacturers (2015-2020) (K MT)
Table 12. Global Biosimilars Insulin Sales Share by Manufacturers (2015-2020)
Table 13. Global Biosimilars Insulin Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Biosimilars Insulin by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biosimilars Insulin as of 2019)
Table 15. Biosimilars Insulin Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Biosimilars Insulin Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Biosimilars Insulin Price (2015-2020) (USD/MT)
Table 18. Biosimilars Insulin Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Biosimilars Insulin Product Type
Table 20. Date of International Manufacturers Enter into Biosimilars Insulin Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Biosimilars Insulin Sales by Type (2015-2020) (K MT)
Table 23. Global Biosimilars Insulin Sales Share by Type (2015-2020)
Table 24. Global Biosimilars Insulin Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Biosimilars Insulin Revenue Share by Type (2015-2020)
Table 26. Biosimilars Insulin Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 27. Global Biosimilars Insulin Sales by Application (2015-2020) (K MT)
Table 28. Global Biosimilars Insulin Sales Share by Application (2015-2020)
Table 29. North America Biosimilars Insulin Sales by Country (2015-2020) (K MT)
Table 30. North America Biosimilars Insulin Sales Market Share by Country (2015-2020)
Table 31. North America Biosimilars Insulin Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Biosimilars Insulin Revenue Market Share by Country (2015-2020)
Table 33. North America Biosimilars Insulin Sales by Type (2015-2020) (K MT)
Table 34. North America Biosimilars Insulin Sales Market Share by Type (2015-2020)
Table 35. North America Biosimilars Insulin Sales by Application (2015-2020) (K MT)
Table 36. North America Biosimilars Insulin Sales Market Share by Application (2015-2020)
Table 37. Europe Biosimilars Insulin Sales by Country (2015-2020) (K MT)
Table 38. Europe Biosimilars Insulin Sales Market Share by Country (2015-2020)
Table 39. Europe Biosimilars Insulin Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Biosimilars Insulin Revenue Market Share by Country (2015-2020)
Table 41. Europe Biosimilars Insulin Sales by Type (2015-2020) (K MT)
Table 42. Europe Biosimilars Insulin Sales Market Share by Type (2015-2020)
Table 43. Europe Biosimilars Insulin Sales by Application (2015-2020) (K MT)
Table 44. Europe Biosimilars Insulin Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Biosimilars Insulin Sales by Region (2015-2020) (K MT)
Table 46. Asia Pacific Biosimilars Insulin Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Biosimilars Insulin Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Biosimilars Insulin Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Biosimilars Insulin Sales by Type (2015-2020) (K MT)
Table 50. Asia Pacific Biosimilars Insulin Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Biosimilars Insulin Sales by Application (2015-2020) (K MT)
Table 52. Asia Pacific Biosimilars Insulin Sales Market Share by Application (2015-2020)
Table 53. Latin America Biosimilars Insulin Sales by Country (2015-2020) (K MT)
Table 54. Latin America Biosimilars Insulin Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Biosimilars Insulin Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Biosimilars Insulin Revenue Market Share by Country (2015-2020)
Table 57. Latin America Biosimilars Insulin Sales by Type (2015-2020) (K MT)
Table 58. Latin America Biosimilars Insulin Sales Market Share by Type (2015-2020)
Table 59. Latin America Biosimilars Insulin Sales by Application (2015-2020) (K MT)
Table 60. Latin America Biosimilars Insulin Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Biosimilars Insulin Sales by Country (2015-2020) (K MT)
Table 62. Middle East and Africa Biosimilars Insulin Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Biosimilars Insulin Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Biosimilars Insulin Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Biosimilars Insulin Sales by Type (2015-2020) (K MT)
Table 66. Middle East and Africa Biosimilars Insulin Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Biosimilars Insulin Sales by Application (2015-2020) (K MT)
Table 68. Middle East and Africa Biosimilars Insulin Sales Market Share by Application (2015-2020)
Table 69. Eli Lilly Corporation Information
Table 70. Eli Lilly Description and Major Businesses
Table 71. Eli Lilly Biosimilars Insulin Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 72. Eli Lilly Product
Table 73. Eli Lilly Recent Development
Table 74. Boehringer Ingelheim Corporation Information
Table 75. Boehringer Ingelheim Description and Major Businesses
Table 76. Boehringer Ingelheim Biosimilars Insulin Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Boehringer Ingelheim Product
Table 78. Boehringer Ingelheim Recent Development
Table 79. Merck Corporation Information
Table 80. Merck Description and Major Businesses
Table 81. Merck Biosimilars Insulin Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. Merck Product
Table 83. Merck Recent Development
Table 84. Pfizer Corporation Information
Table 85. Pfizer Description and Major Businesses
Table 86. Pfizer Biosimilars Insulin Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Pfizer Product
Table 88. Pfizer Recent Development
Table 89. Biocon Corporation Information
Table 90. Biocon Description and Major Businesses
Table 91. Biocon Biosimilars Insulin Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. Biocon Product
Table 93. Biocon Recent Development
Table 94. Mylan Corporation Information
Table 95. Mylan Description and Major Businesses
Table 96. Mylan Biosimilars Insulin Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Mylan Product
Table 98. Mylan Recent Development
Table 99. Global Biosimilars Insulin Sales Forecast by Regions (2021-2026) (K MT)
Table 100. Global Biosimilars Insulin Sales Market Share Forecast by Regions (2021-2026)
Table 101. Global Biosimilars Insulin Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 102. Global Biosimilars Insulin Revenue Market Share Forecast by Regions (2021-2026)
Table 103. North America: Biosimilars Insulin Sales Forecast by Country (2021-2026) (K MT)
Table 104. North America: Biosimilars Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Europe: Biosimilars Insulin Sales Forecast by Country (2021-2026) (K MT)
Table 106. Europe: Biosimilars Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Asia Pacific: Biosimilars Insulin Sales Forecast by Region (2021-2026) (K MT)
Table 108. Asia Pacific: Biosimilars Insulin Revenue Forecast by Region (2021-2026) (US$ Million)
Table 109. Latin America: Biosimilars Insulin Sales Forecast by Country (2021-2026) (K MT)
Table 110. Latin America: Biosimilars Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Middle East and Africa: Biosimilars Insulin Sales Forecast by Country (2021-2026) (K MT)
Table 112. Middle East and Africa: Biosimilars Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 114. Key Challenges
Table 115. Market Risks
Table 116. Main Points Interviewed from Key Biosimilars Insulin Players
Table 117. Biosimilars Insulin Customers List
Table 118. Biosimilars Insulin Distributors List
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilars Insulin Product Picture
Figure 2. Global Biosimilars Insulin Sales Market Share by Type in 2020 & 2026
Figure 3. Insulin Glargine Basaglar Product Picture
Figure 4. Insulin Lantus Product Picture
Figure 5. Global Biosimilars Insulin Sales Market Share by Application in 2020 & 2026
Figure 6. Type I Diabetes
Figure 7. Type II Diabetes
Figure 8. Biosimilars Insulin Report Years Considered
Figure 9. Global Biosimilars Insulin Market Size 2015-2026 (US$ Million)
Figure 10. Global Biosimilars Insulin Sales 2015-2026 (K MT)
Figure 11. Global Biosimilars Insulin Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Global Biosimilars Insulin Sales Market Share by Region (2015-2020)
Figure 13. Global Biosimilars Insulin Sales Market Share by Region in 2019
Figure 14. Global Biosimilars Insulin Revenue Market Share by Region (2015-2020)
Figure 15. Global Biosimilars Insulin Revenue Market Share by Region in 2019
Figure 16. Global Biosimilars Insulin Sales Share by Manufacturer in 2019
Figure 17. The Top 10 and 5 Players Market Share by Biosimilars Insulin Revenue in 2019
Figure 18. Biosimilars Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Biosimilars Insulin Sales Market Share by Type (2015-2020)
Figure 20. Global Biosimilars Insulin Sales Market Share by Type in 2019
Figure 21. Global Biosimilars Insulin Revenue Market Share by Type (2015-2020)
Figure 22. Global Biosimilars Insulin Revenue Market Share by Type in 2019
Figure 23. Global Biosimilars Insulin Market Share by Price Range (2015-2020)
Figure 24. Global Biosimilars Insulin Sales Market Share by Application (2015-2020)
Figure 25. Global Biosimilars Insulin Sales Market Share by Application in 2019
Figure 26. Global Biosimilars Insulin Revenue Market Share by Application (2015-2020)
Figure 27. Global Biosimilars Insulin Revenue Market Share by Application in 2019
Figure 28. North America Biosimilars Insulin Sales Growth Rate 2015-2020 (K MT)
Figure 29. North America Biosimilars Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 30. North America Biosimilars Insulin Sales Market Share by Country in 2019
Figure 31. North America Biosimilars Insulin Revenue Market Share by Country in 2019
Figure 32. U.S. Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 33. U.S. Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Canada Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 35. Canada Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. North America Biosimilars Insulin Market Share by Type in 2019
Figure 37. North America Biosimilars Insulin Market Share by Application in 2019
Figure 38. Europe Biosimilars Insulin Sales Growth Rate 2015-2020 (K MT)
Figure 39. Europe Biosimilars Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. Europe Biosimilars Insulin Sales Market Share by Country in 2019
Figure 41. Europe Biosimilars Insulin Revenue Market Share by Country in 2019
Figure 42. Germany Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 43. Germany Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. France Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 45. France Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. U.K. Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 47. U.K. Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Italy Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 49. Italy Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Russia Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 51. Russia Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Europe Biosimilars Insulin Market Share by Type in 2019
Figure 53. Europe Biosimilars Insulin Market Share by Application in 2019
Figure 54. Asia Pacific Biosimilars Insulin Sales Growth Rate 2015-2020 (K MT)
Figure 55. Asia Pacific Biosimilars Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 56. Asia Pacific Biosimilars Insulin Sales Market Share by Region in 2019
Figure 57. Asia Pacific Biosimilars Insulin Revenue Market Share by Region in 2019
Figure 58. China Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 59. China Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Japan Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 61. Japan Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. South Korea Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 63. South Korea Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. India Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 65. India Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Australia Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 67. Australia Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Taiwan Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 69. Taiwan Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Indonesia Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 71. Indonesia Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Thailand Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 73. Thailand Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Malaysia Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 75. Malaysia Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Philippines Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 77. Philippines Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Vietnam Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 79. Vietnam Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Asia Pacific Biosimilars Insulin Market Share by Type in 2019
Figure 81. Asia Pacific Biosimilars Insulin Market Share by Application in 2019
Figure 82. Latin America Biosimilars Insulin Sales Growth Rate 2015-2020 (K MT)
Figure 83. Latin America Biosimilars Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 84. Latin America Biosimilars Insulin Sales Market Share by Country in 2019
Figure 85. Latin America Biosimilars Insulin Revenue Market Share by Country in 2019
Figure 86. Mexico Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 87. Mexico Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Brazil Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 89. Brazil Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Argentina Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 91. Argentina Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Latin America Biosimilars Insulin Market Share by Type in 2019
Figure 93. Latin America Biosimilars Insulin Market Share by Application in 2019
Figure 94. Middle East and Africa Biosimilars Insulin Sales Growth Rate 2015-2020 (K MT)
Figure 95. Middle East and Africa Biosimilars Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 96. Middle East and Africa Biosimilars Insulin Sales Market Share by Country in 2019
Figure 97. Middle East and Africa Biosimilars Insulin Revenue Market Share by Country in 2019
Figure 98. Turkey Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 99. Turkey Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Saudi Arabia Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 101. Saudi Arabia Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. U.A.E Biosimilars Insulin Sales Growth Rate (2015-2020) (K MT)
Figure 103. U.A.E Biosimilars Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Middle East and Africa Biosimilars Insulin Market Share by Type in 2019
Figure 105. Middle East and Africa Biosimilars Insulin Market Share by Application in 2019
Figure 106. North America Biosimilars Insulin Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 107. North America Biosimilars Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 108. Europe Biosimilars Insulin Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 109. Europe Biosimilars Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Asia Pacific Biosimilars Insulin Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 111. Asia Pacific Biosimilars Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Latin America Biosimilars Insulin Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 113. Latin America Biosimilars Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Middle East and Africa Biosimilars Insulin Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 115. Middle East and Africa Biosimilars Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Porter's Five Forces Analysis
Figure 117. Channels of Distribution
Figure 118. Distributors Profiles
Figure 119. Bottom-up and Top-down Approaches for This Report
Figure 120. Data Triangulation
Figure 121. Key Executives Interviewed
糖尿病用非インスリン療法の世界市場（～2026年） Market Analysis and Insights: Global Non-Insulin Therapies for Diabetes Market The global Non-Insulin Therapies for Diabetes market size is projected to reach US$ 32930 million by 2026, from US$ 30040 million in 2020, at a CAGR of 8.9%% during 2021-2026. Global Non-Insulin Therapies for Diabetes Sco…- CISインスリンの世界市場（～2026年） Insulin is a peptide hormone produced by beta cells of the pancreatic islets, which is considered to be the main anabolic hormone of the body. Russia is estimated to witness a significant growth over the next decade owing to the various subsidies provided by the local government. Market Analysis and…
- モノクローナル抗体(mAb)バイオシミラーの世界市場（～2026年） A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of q…
- インスリン薬・デリバリー技術の世界市場（～2026年） Insulin is a protein hormone that is used as a medication to treat high blood glucose. This includes in diabetes mellitus type 1, diabetes mellitus type 2, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along w…
- インスリンデテミルの世界市場（～2026年） Market Analysis and Insights: Global Insulin Detemir Market The global Insulin Detemir market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Insulin Detemir Scope and Market Size Insulin Detemir market is segmented by Type, …